Search

Your search keyword '"Bonifazi, F."' showing total 807 results
Start Over Author "Bonifazi, F."
807 results on '"Bonifazi, F."'

2. PI-07: THE INTERNATIONAL HEMOGLOBINOPATHY RESEARCH NETWORK (INHERENT): AN INTERNATIONAL INITIATVE TO STUDY THE ROLE OF GENETIC MODIFIERS IN HEMOGLOBINOPATHIES

Author

KOUNTOURIS P., STEPHANOU C., ARCHER N., BONIFAZI F., GIANNUZZI V., KUO K., MAGGIO A., MAKANI J., MAÑÚ PEREIRA M., MICHAILIDOU K., NKYA S., NNODU O., TROMPETER S., TSHILOLO L., WONKAM A., ZILFALIL B., INUSA B., and KLEANTHOUS M.

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

3. Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria)

Author

Olivieri, A., Mancini, G., Olivieri, J., Marinelli Busilacchi, E., Cimminiello, M., Pascale, S. P., Nuccorini, R., Patriarca, F., Corradini, P., Bacigalupo, A., Angelini, S., Poloni, A., Grillo, G., Onida, F., Martino, M., Di Renzo, N., Nagler, A., Mordini, N., Bruno, B., Ciceri, F., and Bonifazi, F.

Published
2020
Full Text
View/download PDF

4. The Italian CART‐SIE real life multicenter observational study on Chimeric Antigen Receptor T‐cell (CAR‐T) therapy for large B‐cell (LBCL) and mantle cell (MCL) lymphomas

Author

Chiappella, A., primary, Dodero, A., additional, Ljevar, S., additional, Pennisi, M., additional, Bonifazi, F., additional, De Philippis, C., additional, Galli, E., additional, Di Rocco, A., additional, Tisi, M. C., additional, Cutini, I., additional, Carrabba, M. G., additional, Musso, M., additional, Martino, M., additional, Barbui, A. M., additional, Botto, B., additional, Farina, M., additional, Grillo, G., additional, Patriarca, F., additional, Ladetto, M., additional, Arcaini, L., additional, Bermema, A., additional, Miceli, R., additional, Magni, M., additional, Zinzani, P. L., additional, Bramanti, S., additional, Chiusolo, P., additional, Martelli, M., additional, Carniti, C., additional, and Corradini, P., additional

Published
2023
Full Text
View/download PDF

5. ‘Real-life’ report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO)

Author

Giaccone, L, Mancini, G, Mordini, N, Gargiulo, G, De Cecco, V, Angelini, S, Arpinati, M, Baronciani, D, Bozzoli, V, Bramanti, S, Calore, E, Cavattoni, I M, Cimminiello, M, Colombo, A A, Facchini, L, Falcioni, S, Faraci, M, Fedele, R, Guidi, S, Iori, A P, Marotta, S, Micò, M C, Milone, G, Onida, F, Pastore, D, Patriarca, F, Pini, M, Raimondi, R, Rovelli, A, Santarone, S, Severino, A, Skert, C, Stanghellini, M T L, Tecchio, C, Vassallo, E, Chiarucci, M, Bruno, B, Bonifazi, F, and Olivieri, A

Published
2018
Full Text
View/download PDF

6. Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System

Author

Della Porta, M G, Jackson, C H, Alessandrino, E P, Rossi, M, Bacigalupo, A, van Lint, M T, Bernardi, M, Allione, B, Bosi, A, Guidi, S, Santini, V, Malcovati, L, Ubezio, M, Milanesi, C, Todisco, E, Voso, M T, Musto, P, Onida, F, Iori, A P, Cerretti, R, Grillo, G, Molteni, A, Pioltelli, P, Borin, L, Angelucci, E, Oldani, E, Sica, S, Pascutto, C, Ferretti, V, Santoro, A, Bonifazi, F, Cazzola, M, and Rambaldi, A

Published
2017
Full Text
View/download PDF

7. Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party

Author

Bento, L, Boumendil, A, Finel, H, Le Gouill, S, Amorim, S, Monjanel, H, Bouabdallah, R, Bay, J O, Nicolas-Virelizier, E, McQuaker, G, Rossi, G, Johnson, R, Huynh, A, Ceballos, P, Rambaldi, A, Bachy, E, Malladi, R, Orchard, K, Pohlreich, D, Tilly, H, Bonifazi, F, Poiré, X, Guilhot, F, Haenel, A, Crawley, C, Metzner, B, Gribben, J, Russell, N H, Damaj, G, Thomson, K, Dreger, P, and Montoto, S

Published
2017
Full Text
View/download PDF

8. Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study

Author

Malagola, M., Polverelli, N., Martino, M., Patriarca, F., Bruno, B., Giaccone, L., Grillo, G., Bramanti, S., Bernasconi, P., De Gobbi, M., Natale, A., Terruzzi, E., Olivieri, A., Chiusolo, P., Carella, A. M., Casini, M., Maffini, E., Nozzoli, C., Mazza, P., Bassi, S., Onida, F., Vacca, A., Falcioni, S., Luppi, M., Iori, A. P., Pavone, V., Skert, C., Carluccio, P., Borghero, C., Proia, A., Selleri, C., Rubini, V., Sacchi, N., Oldani, E., Bonifazi, F., Ciceri, F., Russo, D., Bernardi, S., Farina, M., Fiore, M., Lupo Stanghellini, M. T., Fanin, R., Faraci, D. G., Castagna, L., Colombo, A. A., Nicoli, P., Santarone, S., Scortechini, I., Metafuni, E., Merla, E., Cavattoni, I., Cutini, I., Mazzone, A., Saporiti, G., Canale, F. A., Piras, E., Galieni, P., Debbia, G., La Rocca, U., Mele, A., Carobolante, F., Elice, F., and Fanelli, F.

Subjects
Busulfan, Treosulfan, stem cell transplant, Transplantation
Published
2023

11. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party

Author

Sobh, M, Michallet, M, Gahrton, G, Iacobelli, S, van Biezen, A, Schönland, S, Petersen, E, Schaap, N, Bonifazi, F, Volin, L, Meijer, E, Niederwieser, D, El-Cheikh, J, Tabrizi, R, Fegeux, N, Finke, J, Bunjes, D, Cornelissen, J, Einsele, H, Bruno, B, Potter, M, Fanin, R, Mohty, M, Garderet, L, and Kröger, N

Published
2016
Full Text
View/download PDF

12. P1481: THE INTERNATIONAL HEMOGLOBINOPATHY RESEARCH NETWORK (INHERENT): AN INTERNATIONAL INITIATIVE TO STUDY THE ROLE OF GENETIC MODIFIERS IN HEMOGLOBINOPATHIES

Author

Kountouris, P., primary, Stephanou, C., additional, Archer, N., additional, Bonifazi, F., additional, Giannuzzi, V., additional, Kuo, K., additional, Maggio, A., additional, Makani, J., additional, Mañú Pereira, M. D. M., additional, Michailidou, K., additional, Nkya, S. W., additional, Nnodu, O., additional, Trompeter, S., additional, Tshilolo, L., additional, Wonkam, A., additional, Zilfalil, B. A., additional, Inusa, B., additional, and Kleanthous, M., additional

Published
2022
Full Text
View/download PDF

13. RItA: The Italian severe/uncontrolled asthma registry

Author

Maio, S., Baldacci, S., Bresciani, M., Simoni, M., Latorre, M., Murgia, N., Spinozzi, F., Braschi, M., Antonicelli, L., Brunetto, B., Iacovacci, P., Roazzi, P., Pini, C., Pata, M., La Grasta, L., Paggiaro, P., Viegi, G., Angino, A., Carrozzi, L., Cerrai, S., Di Pede, F., Martini, F., Pala, A.P., Pistelli, F., Sarno, G., Silvi, P., Novelli, F., Ferri, M., Bonifazi, F., and Viegi, G.

Published
2018
Full Text
View/download PDF

14. Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey)

Author

Russo D., Polverelli N., Malagola M., Farina M., Leoni A., Bernardi S., Mammoliti S., Sacchi N., Martino M., Ciceri F., Zallio F., Olivieri A., Falcioni S., Storti G., Michieli M., Carluccio P., Grassi A., Oldani E., Bonifazi F., Prete A., Cavattoni I. M., Maffeis M., Pastore D., Vacca A., Caravelli D., Mirabile M., Mordini N., Nozzoli C., Faraci M., Federico V., Ronconi S., Skert C., Onida F., Marcatti M., Piemontese S., Narni F., Balduzzi A., De Simone G., Picardi A., De Gobbi M., Calore E., Tringali S., Zecca M., Secondino S., Guiducci B., Pelosini M., Zuffa E., Facchini L., Imola M., Iori A. P., Proia A., Sica S., Armiento D., Carella A. M., Dellacasa C. M., Fagioli F., Rabusin M., Ferrario A., Elice F., Russo, D, Polverelli, N, Malagola, M, Farina, M, Leoni, A, Bernardi, S, Mammoliti, S, Sacchi, N, Martino, M, Ciceri, F, Zallio, F, Olivieri, A, Falcioni, S, Storti, G, Michieli, M, Carluccio, P, Grassi, A, Oldani, E, Bonifazi, F, Prete, A, Cavattoni, I, Maffeis, M, Pastore, D, Vacca, A, Caravelli, D, Mirabile, M, Mordini, N, Nozzoli, C, Faraci, M, Federico, V, Ronconi, S, Skert, C, Onida, F, Marcatti, M, Piemontese, S, Narni, F, Balduzzi, A, De Simone, G, Picardi, A, De Gobbi, M, Calore, E, Tringali, S, Zecca, M, Secondino, S, Guiducci, B, Pelosini, M, Zuffa, E, Facchini, L, Imola, M, Iori, A, Proia, A, Sica, S, Armiento, D, Carella, A, Dellacasa, C, Fagioli, F, Rabusin, M, Ferrario, A, Elice, F, Russo, D., Polverelli, N., Malagola, M., Farina, M., Leoni, A., Bernardi, S., Mammoliti, S., Sacchi, N., Martino, M., Ciceri, F., Zallio, F., Olivieri, A., Falcioni, S., Storti, G., Michieli, M., Carluccio, P., Grassi, A., Oldani, E., Bonifazi, F., Prete, A., Cavattoni, I. M., Maffeis, M., Pastore, D., Vacca, A., Caravelli, D., Mirabile, M., Mordini, N., Nozzoli, C., Faraci, M., Federico, V., Ronconi, S., Skert, C., Onida, F., Marcatti, M., Piemontese, S., Narni, F., Balduzzi, A., De Simone, G., Picardi, A., De Gobbi, M., Calore, E., Tringali, S., Zecca, M., Secondino, S., Guiducci, B., Pelosini, M., Zuffa, E., Facchini, L., Imola, M., Iori, A. P., Proia, A., Sica, S., Armiento, D., Carella, A. M., Dellacasa, C. M., Fagioli, F., Rabusin, M., Ferrario, A., and Elice, F.

Subjects
Homologous, Myeloid, medicine.medical_specialty, 2019-20 coronavirus outbreak, Bone marrow transplant, Coronavirus disease 2019 (COVID-19), Epidemiology, medicine.medical_treatment, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Hematopoietic stem cell transplantation, Acute, Humans, Italy, Pandemics, RNA, Viral, SARS-CoV-2, Stem Cell Transplantation, Transplantation, Homologous, COVID-19, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute, Article, hematopoietic stem cell transplantation, covid-19, pandemic, Internal medicine, Pandemic, medicine, Viral, Acute leukemia, Transplantation, Leukemia, business.industry, Hematology, Stem-cell research, RNA, Stem cell, business
Abstract

The Transplant Centers belonging to Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO) conducted a survey with the aim of evaluating the effect of SARS-CoV2 pandemic on the allogeneic transplant activity in Italy. The pandemic period from 1/3/2020 to 31/7/2020 was compared with the same period in 2019. Overall, in 2020 there was a 2.4% reduction in the number of allo-HCT cases compared to 2019. Interestingly, this deflection did not affect the acute leukemia cases (+5.7% in 2020). The use of peripheral blood-derived stem cells (+10.7%) and cryopreservation (97.4% of the centers) was highly adopted in 2020. Despite the sanitary emergency, almost all of the surveyed centers declared no impact of SARS-CoV2 pandemic on the transplant timing and outcomes, and the sanitary policy was positively evaluated by the majority of centers. The emergency measures ensured that only a minority of the allo-HCT patients had been infected by SARS-CoV2; however, a mortality of 42.1% among the allo-HCT patients hospitalized for COVID-19 was recorded. This survey gives us the information that the GITMO Group reacted positively to the pandemic. Thanks to the emergency strategies, the Italian allo-HCT activity continued safely, showing only a minor deflection and offering the same probability of cure to the transplanted patients.

Published
2021

16. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT

Author

Cahu, X, Labopin, M, Giebel, S, Aljurf, M, Kyrcz-Krzemien, S, Socié, G, Eder, M, Bonifazi, F, Bunjes, D, Vigouroux, S, Michallet, M, Stelljes, M, Zuckerman, T, Finke, J, Passweg, J, Yakoub-Agha, I, Niederwieser, D, Sucak, G, Sengeløv, H, Polge, E, Nagler, A, Esteve, J, and Mohty, M

Published
2016
Full Text
View/download PDF

18. Cytomegalovirus and Epstein-Barr Virus DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplantation Recipients

Author

Lazzarotto T, Chiereghin A, Piralla A, Piccirilli G, Girello A, Campanini G, Gabrielli L, Costa C, Prete A, Bonifazi F, Busca A, Cairoli R, Colombo AA, Zecca M, Sidoti F, Bianco G, Paba P, Perno CF, Cavallo R, Baldanti F, AMCLI-GLaIT working group., Lazzarotto T, Chiereghin A, Piralla A, Piccirilli G, Girello A, Campanini G, Gabrielli L, Costa C, Prete A, Bonifazi F, Busca A, Cairoli R, Colombo AA, Zecca M, Sidoti F, Bianco G, Paba P, Perno CF, Cavallo R, Baldanti F, AMCLI-GLaIT working group., Tiziana, L, Angela, C, Antonio, P, Giulia, P, Alessia, G, Giulia, C, Liliana, G, Cristina, C, Arcangelo, P, Francesca, B, Alessandro, B, Cairoli, R, Anna Amelia, C, Marco, Z, Francesca, S, Gabriele, B, Pierpaolo, P, Carlo Federico, P, Rossana, C, and Fausto, B

Subjects
Adult, Male, 0301 basic medicine, Herpesvirus 4, Human, medicine.medical_specialty, medicine.medical_treatment, 030106 microbiology, Congenital cytomegalovirus infection, Allogeneic hematopoietic stem cell transplantation, CMV and EBV DNA kinetics, Plasma, Whole blood, Hematology, Transplantation, Cytomegalovirus, Hematopoietic stem cell transplantation, Virus Replication, Virus, 03 medical and health sciences, chemistry.chemical_compound, Internal medicine, medicine, Humans, Aged, Retrospective Studies, CMV and EBV DNA kinetic, business.industry, Hematopoietic Stem Cell Transplantation, virus diseases, Middle Aged, Allografts, medicine.disease, Virology, Transplant Recipients, Kinetics, Blood, 030104 developmental biology, chemistry, Viral replication, DNA, Viral, Female, business, DNA
Abstract

Currently, no consensus has been reached on the optimal blood compartment to be used for surveillance of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) DNAemia. Although several comparative studies have been performed correlating CMV and EBV DNA loads in whole blood (WB) versus plasma, to our knowledge, no studies to date have analyzed the kinetics of both viruses in the 2 blood compartments. In this retrospective noninterventional multicenter cohort study, the kinetics of CMV and EBV DNA in 121 hematopoietic stem cell transplantation (HSCT) recipients were investigated by analyzing in parallel 569 and 351 paired samples from 80 and 58 sequential episodes of CMV and EBV DNAemia, respectively. Unlike previous studies, this study used a single automated molecular method that was CE-marked and Food and Drug Administration-approved for use in quantifying CMV and EBV DNA in both plasma and WB. Furthermore, the complete viral replication kinetics of all episodes (including both the ascending and the descending phases of the active infection) was examined in each patient. The previously observed overall correlation between CMV DNA levels in WB and plasma was confirmed (Spearman's ρ =.85; P

Published
2018

19. Long‐term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high‐risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party‐EBMT

Author

Gutiérrez‐García, G., primary, Martínez, C., additional, Boumendil, A., additional, Finel, H., additional, Malladi, R., additional, Afanasyev, B., additional, Tsoulkani, A., additional, Wilson, K. M. O., additional, Bloor, A., additional, Nikoloudis, M., additional, Richardson, D., additional, López‐Corral, L., additional, Castagna, L., additional, Cornelissen, J., additional, Giltat, A., additional, Collin, M., additional, Fanin, R., additional, Bonifazi, F., additional, Robinson, S., additional, Montoto, S., additional, Peggs, K. S., additional, and Sureda, A., additional

Published
2021
Full Text
View/download PDF

20. Comparative evaluation of biological HLA-DPB1 mismatch models for survival and graft versus host disease prediction after unrelated donor hematopoietic cell transplantation

Author

Lorentino, F, Sacchi, N, Oldani, E, Miotti, V, Picardi, A, Gallina, Am, Crivello, P, Bernasconi, P, Saccardi, R, Farina, L, Benedetti, F, Cerno, M, Grassi, A, Bruno, B, Patriarca, F, Ciceri, F, Fleischhauer, K, Vago, L, Bonifazi, F, Lorentino, F., Sacchi, N., Oldani, E., Miotti, V., Picardi, A., Gallina, A. M., Crivello, P., Bernasconi, P., Saccardi, R., Farina, L., Benedetti, F., Cerno, M., Grassi, A., Bruno, B., Patriarca, F., Ciceri, F., Fleischhauer, K., Vago, L., and Bonifazi, F.

Subjects
HLA, Graft-versus-Host-Disease, unrelated donor selection, Medizin, Settore MED/15, Stem Cell Transplantation
Abstract

CA Fleischhauer

Published
2020

21. FDG‐PET IMAGING AND RADIOMICS IN RESPONSE ASSESSMENT OF LYMPHOMA PATIENTS UNDERGOING CAR T‐CELL THERAPY

Author

Casadei, B., primary, Paccagnella, A., additional, Farolfi, A., additional, Argnani, L., additional, Malizia, C., additional, Paolani, G., additional, Santoro, M., additional, Della Gala, G., additional, Strolin, S., additional, Strigari, L., additional, Guadagnuolo, S., additional, Bonifazi, F., additional, Fanti, S., additional, and Zinzani, P. L., additional

Published
2021
Full Text
View/download PDF

25. MULTI-GENOTYPING OF MINOR HISTOCOMPATIBILITY ANTIGENS (MHAGS) IN ALLOGENEIC STEM CELL TRANSPLANTATION AND THEIR ROLE IN DETERMINING GRAFT VERSUS HOST DISEASE (GVHD) AND GRAFT VERSUS LEUKEMIA (GVL) EFFECT: PH-P109

Author

Cattina, F., Skert, C., Bernardi, S., Malagola, M., Ottaviani, E., Bochicchio, M. T., Iacobucci, I., Soverini, S., Bonifazi, F., Bandini, G., Arpinati, M., Motta, M. R., Toffoletti, E., Damiani, D., Santoro, A., Fabbiano, F., Pastore, D., Specchia, G., Console, G., Bruno, M., Carella, G., Malagoli, A., Guadagnuolo, V., De Benedittis, C., Bergonzi, C., Filì, C., Turra, A., Ribolla, R., Cancelli, V., Alghisi, E., Perucca, S., Di Palma, A., Martinelli, G., and Russo, D.

Published
2014

26. Ocular Graft Versus-host Disease Patients Exhibit Impaired Corneal Biomechanics

Author

Giannaccare, G, Pellegrini, M, Taroni, L, Bernabei, F, Senni, C, Grendele, A, Moscardelli, F, Arpinati, M, Bonifazi, F, Sessa, M, Versura, P, Campos, EC, Giannaccare, G, Pellegrini, M, Taroni, L, Bernabei, F, Senni, C, Grendele, A, Moscardelli, F, Arpinati, M, Bonifazi, F, Sessa, M, Versura, P, and Campos, EC

Subjects
Ocular GVHD, MMP-9, ocular surface, dry eye, inflammation
Abstract

Increased levels of tear matrix metalloproteinase-9 (MMP-9) have been detected in ocular graft versus host disease (oGVHD) patients. Since MMP-9 is a proteolytic enzyme involved in the degradation of corneal extracellular matrix components, we hypothesized that higher tears levels of MMP-9 might impair corneal biomechanics. Therefore, the purpose of this study was to compare corneal biomechanical properties between patients with oGVHD and healthy matched subjects, and to further correlate these values with ocular surface characteristics.

Published
2019

27. Long‐term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high‐risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party‐EBMT.

Author

Gutiérrez‐García, G., Martínez, C., Boumendil, A., Finel, H., Malladi, R., Afanasyev, B., Tsoulkani, A., Wilson, K. M. O., Bloor, A., Nikoloudis, M., Richardson, D., López‐Corral, L., Castagna, L., Cornelissen, J., Giltat, A., Collin, M., Fanin, R., Bonifazi, F., Robinson, S., and Montoto, S.

Subjects
HEMATOPOIETIC stem cell transplantation, HODGKIN'S disease, TRANSPLANTATION of organs, tissues, etc., LYMPHOMAS, TREATMENT effectiveness
Abstract

Summary: We analysed long‐term outcome of patients receiving haematopoietic allogeneic stem cell transplantation (allo‐HSCT) as a first transplant for high‐risk Hodgkin lymphoma (HL). One hundred and ninety patients were included in this study, 63% of them had previously received brentuximab vedotin and/or checkpoint inhibitors. Seventy patients (37%) received an unrelated donor allo‐HSCT, 99 (51%) had myeloablative conditioning (MAC) and 60% had in vivo T‐cell/depleted grafts (TCD). The 100‐day cumulative incidence (CI) of grade II‐IV acute graft‐versus‐host disease (GVHD) was 25% and the 3‐year CI of chronic GVHD was 38%. The 3‐year CI of non‐relapse mortality (NRM) and relapse rate were 21% and 38% respectively. After a median follow‐up of 58 months, 3‐year overall survival (OS) and progression‐free survival (PFS) were 58% and 41% respectively. Multivariate analysis showed that, in comparison to reduced‐intensity conditioning regimens with or without TCD, MAC using TCD had similar NRM and a lower risk of relapse leading to significantly better OS and PFS. MAC without TCD was associated with higher NRM and worse survival outcomes. These results suggest that in patients with high‐risk HL and candidates of allo‐HSCT, a MAC strategy with TCD might be the best option. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

28. The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo

Author

Todisco, E, Ciceri, F, Oldani, E, Boschini, C, Micò, C, VanLint, M T, Donnini, I, Patriarca, F, Alessandrino, P E, Bonifazi, F, Arcese, W, Barberi, W, Marenco, P, Terruzzi, E, Cortelazzo, S, Santarone, S, Proia, A, Corradini, P, Tagliaferri, E, Falcioni, S, Irrera, G, Dallanegra, L, Castagna, L, Santoro, A, Camboni, A, Sacchi, N, Bosi, A, Bacigalupo, A, and Rambaldi, A

Published
2013
Full Text
View/download PDF

30. A comparison of data-access platforms for the computing of Large Hadron Collider experiments

Author

Bencivenni, M., Bonifazi, F., Carbone, A., Chierici, A., D'Apice, A., De Girolamo, D., dell'Agnello, L., Donatelli, M., Donvito, G., Fella, A., Furano, F., Galli, D., Ghiselli, A., Italiano, A., Re, G. Lo, Marconi, U., Martelli, B., Mazzucato, M., Onofri, M., Ricci, P.P., Rosso, F., Salomoni, D., Sapunenko, V., Vagnoni, V., Veraldi, R., Vistoli, M.C., Vitlacil, D., and Zani, S.

Subjects
Nuclear research -- Equipment and supplies, Collisions (Nuclear physics) -- Research, Electronic data processing -- Methods, System design -- Methods, Systems analysis -- Methods, Memory (Computers) -- Evaluation, System design, Semiconductor memory, Business, Electronics, Electronics and electrical industries
Abstract

Performance, reliability and scalability in data-access are key issues in the context of the computing Grid and High Energy Physics data processing and analysis applications, in particular considering the large data size and I/O load that a Large Hadron Collider data centre has to support. In this paper we present the technical details and the results of a large scale validation and performance measurement employing different data-access platforms--namely CASTOR, dCache, GPFS and Scalla/Xrootd. The tests have been performed at the CNAF Tier-l, the central computing facility of the Italian National Institute for Nuclear Research (INFN). Our storage back-end was based on Fibre Channel disk-servers organized in a Storage Area Network, being the disk-servers connected to the computing farm via Gigabit LAN. We used 24 disk-servers, 260 TB of raw-disk space and 280 worker nodes as computing clients, able to run concurrently up to about 1100 jobs. The aim of the test was to perform sequential and random read/write accesses to the data, as well as more realistic access patterns, in order to evaluate efficiency, availability, robustness and performance of the various data-access solutions. Index Terms--Computer facilities, computer input-output, data handling, data processing, mass memories, system analysis and design.

Published
2008

31. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome

Author

Corradini, P, Dodero, A, Farina, L, Fanin, R, Patriarca, F, Miceli, R, Matteucci, P, Bregni, M, Scimè, R, Narni, F, Pogliani, E, Locasciulli, A, Milani, R, Carniti, C, Bacigalupo, A, Rambaldi, A, Bonifazi, F, Olivieri, A, Gianni, A M, and Tarella, C

Published
2007
Full Text
View/download PDF

33. Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group

Author

Gori, E, Arpinati, M, Bonifazi, F, Errico, A, Mega, A, Alberani, F, Sabbi, V, Costazza, G, Leanza, S, Borrelli, C, Berni, M, Feraut, C, Polato, E, Altieri, M C, Pirola, E, Loddo, M C, Banfi, M, Barzetti, L, Calza, S, Brignoli, C, Bandini, G, De Vivo, A, Bosi, A, and Baccarani, M

Published
2007
Full Text
View/download PDF

34. Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel

Author

Bonifazi F, Rubio M, Bacigalupo A, Boelens J, Finke J, Greinix H, Mohty M, Nagler A, Passweg J, Rambaldi A, Socie G, Solano C, Walker I, Barosi G, and Kroger N

Subjects
surgical procedures, operative
Abstract

This collaborative initiative aimed to provide recommendations on the use of polyclonal antithymocyte globulin (ATG) or anti-T lymphocyte globulin (ATLG) for the prevention of graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HSCT). A comprehensive review of articles released up to October, 2018 was performed as a source of scientific evidence. Fourteen clinically relevant key questions to the domains indication, administration, and post-transplant management were developed and recommendations were produced using the Delphi technique involving a Panel of 14 experts. ATG/ATLG was strongly recommended as part of myeloablative conditioning regimen prior to matched or mismatched unrelated bone marrow or peripheral blood allogeneic HSCT in malignant diseases to prevent severe acute and chronic GvHD. ATG/ATLG was also recommended prior to HLA-identical sibling peripheral HSCT with good but lesser bulk of evidence. In reduced intensity or nonmyeloablative conditioning regimens, ATG/ATLG was deemed appropriate to reduce the incidence of acute and chronic GvHD, but a higher risk of relapse should be taken into account. Recommendations regarding dose, application, and premedication were also provided as well as post-transplant infectious prophylaxis and vaccination. Overall, these recommendations can be used for a proper and safe application of polyclonal ATG/ATLG to prevent GvHD after allogeneic HSCT.

Published
2020

37. RItA: The Italian severe/uncontrolled asthma registry

Author

Maio, S., Baldacci, S., Bresciani, M., Simoni, M., Latorre, M., Murgia, N., Spinozzi, F., Braschi, M., Antonicelli, L., Brunetto, B., Iacovacci, P., Roazzi, P., Pini, C., Pata, M., La Grasta, L., Paggiaro, P., Viegi, G., Angino, A., Carrozzi, L., Cerrai, S., Di Pede, F., Martini, F., Pala, A. P., Pistelli, F., Sarno, G., Silvi, P., Novelli, F., Ferri, M., and Bonifazi, F.

Subjects
Adult, Male, severe/uncontrolled asthma, medicine.medical_specialty, Exacerbation, Immunology, NO, 03 medical and health sciences, 0302 clinical medicine, exacerbations, pharmacological treatment, Internal medicine, eosinophilic inflammation, medicine, Humans, Immunology and Allergy, Nasal polyps, Registries, 030212 general & internal medicine, Sinusitis, Aged, Asthma, business.industry, Comorbidity, Eosinophilic inflammation, Exacerbations, Pharmacological treatment, Severe/uncontrolled asthma, Emergency department, Middle Aged, medicine.disease, Obesity, Allergic conjunctivitis, comorbidity, Italy, 030228 respiratory system, comorbidity, eosinophilic inflammation, exacerbations, pharmacological treatment, severe/uncontrolled asthma, Physical therapy, Female, business
Abstract

Background The Italian severe/uncontrolled asthma (SUA) web-based registry encompasses demographic, clinical, functional, inflammatory data; it aims to raise SUA awareness, identifying specific phenotypes and promoting optimal care. Methods 493 adult patients from 27 Italian centres (recruited in 2011-2014) were analyzed. Results Mean age was 53.8yrs. SUA patients were more frequently female (60.6%), with allergic asthma (83.1%). About 30% showed late onset of asthma diagnosis/symptoms (>40yrs); the mean age for asthma symptoms onset was 30.2yrs and for asthma diagnosis 34.4yrs. 97.1% used ICS (dose 2000 BDP), 93.6% LABA in association with ICS, 53.3% LTRAs, 64.1% anti-IgE, 10.7% theophylline, 16.0% oral corticosteroids. Mean FEV1% pred of 75.1%, median values of 300/mm3 of blood eosinophil count, 323 kU/l of serum total IgE, 24 ppb of FENO were shown. Most common comorbidities were allergic rhinitis (62.4%), gastroesophageal reflux (42.1%), sinusitis (37.9%), nasal polyposis (30.2%), allergic conjunctivitis (30.2%). 55.7% of SUA patients had exacerbations in the last 12 months, 9.7% emergency department visits, 7.3% hospitalizations. Factors associated with exacerbation risk were: obesity (OR, 95%CI 2.46, 1.11-5.41), psychic disorders (2.87, 0.89-9.30 - borderline), nasal polyps (1.86, 0.88-3.89 - borderline), partial/poor asthma treatment adherence (2.54, 0.97-6.67 - borderline), anti-IgE use in a protective way (0.26, 0.12-0.53). Comparisons to severe asthma multicentre studies and available registries showed data consistency across European and American populations. Conclusions An international effort in the implementation of SUA patients registries could help to better understand the clinical features and to manage severe asthma, representing a non negligible socio-economic burden for health services. This article is protected by copyright. All rights reserved.

Published
2017

42. Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients

Author

Rambaldi, A, Bacigalupo, A, Fanin, R, Ciceri, F, Bonifazi, F, Falda, M, Lambertenghi-Deliliers, G, Benedetti, F, Bruno, B, Corradini, P, Alessandrino, P E, Iacopino, P, Arcese, W, Scimè, R, Raimondi, R, Sica, S, Castagna, L, Lamparelli, T, Oneto, R, Lombardini, L, Pollichieni, S, Algarotti, A, Carobbio, A, Sacchi, N, and Bosi, A

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results